By Andrea Eisenman
Seventeen years ago I was just going through the motions of trying to keep pushing towards each day with a schedule of treatments, eating, napping, lung bleeds and more treatments. Then starting all over again the following day with Continue reading From Sustaining and Surviving – to Living!
Pulmatrix, Inc. (NASDAQ: PULM) announced today that its Chief Scientific Officer, David L. Hava, PhD, has written an article in ONdrugDelivery Magazine highlighting advances in delivering drugs to the lungs to fight Continue reading Advances in Inhaled Drug Delivery Offer Major Benefits to Patients, Chief Scientific Officer for Pulmatrix Explains in Article
Kitabis Pak, the first co-packaging of generic tobramycin inhalation solution with a PARI LC PLUS Nebulizer for cystic fibrosis, was among ten notable drug-device approvals of 2014 published in the current issue of Drug Development & Continue reading Kitabis Pak One of Ten Notable Drug-Device Approvals of 2014
PARI Pharma’s Vantobra®, a new highly concentrated tobramycin nebuliser solution for inhalation delivered by a Tolero® nebuliser, was granted Marketing Authorisation from the European Commission in mid-March. Vantobra is a breakthrough for cystic fibrosis patients as it offers Continue reading PARI Pharma’s Vantobra Granted Marketing Authorisation in Europe
The first patient has been enrolled in the PARI PROVIDE compressor access program to accompany the launch of Kitabis Pak. FDA approved Kitabis Pak as a drug and device combination – the first co-packaging of generic tobramycin inhalation solution with a PARI LC Continue reading 1st Patient Enrolled in PARI PROVIDE; New Compressor Access Program for Kitabis Pak Patients